<DOC>
	<DOC>NCT00286000</DOC>
	<brief_summary>A multicentre phase II study to evaluate the results of high dose simplified folfiri in advanced colorectal cancer</brief_summary>
	<brief_title>High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically or cytologically proven adenocarcinoma of the colon or rectum Documented progressive metastatic disease Patients who have at least one unidimensional measurable lesion by CTscan or MRI according to response evaluation criteria in solid tumours (RECIST) WHO performance status of 0 or 1 Adequate laboratory values of haematology, liverfunction and renal function No previous chemotherapy for metastatic colorectal cancer Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except curatively treated cancer free of disease for more than 10 years. Bowel obstruction or subobstruction. Crohn's disease, or ulcerative colitis. Other severe illness or medical condition such as unstable cardiac disease under treatment, myocardial infarction within 6 months before inclusion. Active uncontrolled infection Other concomitant anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>